| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | LIM/homeobox protein Lhx1; LIM homeobox protein 1; Homeobox protein Lim-1; hLim-1; LHX1; LIM-1; LIM1 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived human LIM1/LHX1 recombinant protein (Position: M1-S317). |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-LIM1/LHX1 Antibody Picoband® is an antibody for LHX1 detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Human,Mouse. Commonly used in WB, IHC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: LHX1 (LIM homeobox 1); UniProt: P48742
- Antibody format: Rabbit, Polyclonal, Rabbit IgG
- Molecular weight: 43 kDa, calculated 45672 MW
- Applications: WB, IHC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-LIM1/LHX1 Antibody Picoband® catalog # A05816-1.
Biological background
Biological context: Potential transcription factor. May play a role in early mesoderm formation and later in lateral mesoderm differentiation and neurogenesis.
Expression and localization notes: cellular localization: Nucleus., tissue context: Expressed in the brain, thymus, and tonsils. Expressed in samples from patients with chronic myeloid leukemia (CML) and in 58% of acute myeloid leukemia (AML) cell lines..
Common research applications
- Western blotting (WB): Compare LHX1 levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of LHX1 in tissue sections, considering fixation and antigen retrieval effects.
- Flow cytometry: Quantify LHX1-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Specificity: No cross reactivity with other proteins.
- Background: LIM homeobox 1 is a protein that in humans is encoded by the LHX1 gene. It is mapped to 17q12. This gene encodes a member of a large protein family which contains the LIM domain, a unique cysteine-rich zinc-binding domain. The encoded protein is a transcription factor important for the development of the renal and urogenital systems. This gene is a candidate for Mayer-Rokitansky-Kuster-Hauser syndrome, a disorder characterized by anomalies in the female genital tract.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Nucleus.
- Tissue details: Expressed in the brain, thymus, and tonsils. Expressed in samples from patients with chronic myeloid leukemia (CML) and in 58% of acute myeloid leukemia (AML) cell lines.
- Research category: Chromatin Binding Proteins,DNA/RNA,DNA/RNA Binding,Epigenetics and Nuclear Signaling,RNA Processing,Splicing
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
